|
|
JACKSON CENTER, PA / ACCESSWIRE / September 27, 2022 / Halberd Corporation OTC PINK:HALB entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named "ExtendalifeTM." The mission will be to develop treatments intended to increase longevity and develop successful Alzheimers Disease and... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / August 23, 2022 / Halberd Corporation OTC PINK:HALB researchers have demonstrated the ability to precisely control the level of PD1 in human blood serum in laboratory invitro testing. PD1 programmed cell death1 is a TCell protein which can be used by tumor cells to fool the bodys immune system into allowing the tumor to grow[1]. Halberds extracorporeal process,... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / August 4, 2022 / Halberd Corporation OTC PINK:HALB has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association NFL RPA, for Halberds research work in the development of treatments for Traumatic Brain Injury TBI/chronic traumatic encephalopathy CTE sustained by current and retired players. Traumatic brain injuries often... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation OTC PINK:HALB announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberds patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and healthrelated illnesses. For now, the new entity will be staffed by Halberd personnel... Lire le communiqué |
|
| |
|
| |
|
|
Boosts Effectiveness of Commercial Covid Antibodies by 45%JACKSON CENTER, PA / ACCESSWIRE / July 14, 2022 / Halberd Corporation OTC PINK:HALB researchers developed, with appropriate protocols, a SARSCoV2 antibody effective against all four Covid19 mutations currently in circulation, including Omicron. When Halberds antibody was combined with a leading commercially available Covid19 antibody... Lire le communiqué |
|
| |
|
| |
|
|
Q2 Accomplishments and a Look to the FutureJACKSON CENTER, PA / ACCESSWIRE / July 12, 2022 / Halberd Corporation OTC PINK:HALB This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the Second Quarter ending June 30, 2022, are as follows:2Q ACHIEVEMENTSAdded an animal testing... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation OTC PINK:HALB announced the creation of a subgroup of researchers to focus on cancer treatment. Halberds technology is capable of being applied to many diseases, and management decided to not delay the development of potential cancer... Lire le communiqué |
|
| |
|
| |
